Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer (2019) Mamounas EP, Geyer CE, Huang CS, Mano MS, Loibl S, Untch M, Wolmark N, et al. Conference contribution Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study (2019) Wallwiener M, Nabieva N, Feisst M, Fehm T, De Waal J, Rezai M, Baier B, et al. Journal article Categorical EHR imputation with generative adversarial nets (2019) Yang Y, Wu Z, Tresp V, Fasching P Conference contribution Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis (2019) Shu X, Wu L, Khankari NK, Shu XO, Wang TJ, Michailidou K, Bolla MK, et al. Journal article The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis (2019) Ooi BNS, Loh H, Ho PJ, Milne RL, Giles G, Gao C, Kraft P, et al. Journal article Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study (2019) Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne CH, Solbach C, et al. Journal article Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study (2019) Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus , Foerster F, Grischke EM, et al. Journal article Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk (2019) Vachon CM, Scott CG, Tamimi RM, Thompson DJ, Fasching P, Stone J, Southey MC, et al. Journal article Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto (2019) Laakmann E, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, et al. Journal article Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials (2019) Jank P, Loibl S, Fasching P, Karn T, Marme F, Mueller V, Schem C, et al. Conference contribution